Aaron H. Rousso, APRN, FNP-BC
- Ozone Therapy
- IV Therapy
- IV Hydration
- Ketamine Therapy
- Arthritis Treatment
Wellington, FL
Wellington has an equestrian community with a seasonal international patient base, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across Palm Beach Polo, the Mall at Wellington Green area, and Binks Forest range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Wellington Regional Medical Center and Palms West network. The scene here skews toward concierge clinics serving equestrian professionals and seasonal residents. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Wellington clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Regulatory context
Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. The FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list during 2023 and 2024, restricting which peptides 503A compounding pharmacies may source for patient-specific prescriptions. Section 503A applies to traditional compounding pharmacies; Section 503B governs FDA-registered outsourcing facilities operating under cGMP.
Florida hosts a large compounding pharmacy market, including Wells Pharmacy Network and other major peptide compounders. The Florida Board of Pharmacy has issued disciplinary actions for sterile compounding deficiencies and for sourcing ingredients inconsistent with FDA bulk substance rules. Non-resident pharmacies shipping into Florida must hold a current non-resident permit. Florida is also a high-volume market for medical spas and peptide clinics, which receives ongoing regulatory attention.